Brind.

FDA Review Statuses: Savara Molgramostim Review Ongoing; Capricor Receives Rejection

1 report, 1 independent Updated 05:34
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA confirmed that the review of Savara Inc.'s inhaled drug, molgramostim, will not meet its goal date of November 22, 2026, and no new date has been set. The agency stated the review remains ongoing and did not issue a formal rejection letter. Separately, the FDA issued a rejection to Capricor Therapeutics for its cell therapy, deramiocel.

From techtimes.com

Why it matters

Some supportBrind's analysis of the reports

Regulatory decisions regarding new treatments directly impact market supply and demand for specific diseases. The rejection of Capricor's deramiocel and the delay in the molgramostim review affect the availability of treatments for autoimmune pulmonary alveolar proteinosis in the United States.

From techtimes.com

Who's involved

  • FDARegulatory agency that reviewed the drug applications for Savara Inc. and Capricor Therapeutics

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • The market for autoimmune pulmonary alveolar proteinosis treatments might see changes in demand due to the rejection of Capricor Therapeutics' deramiocel.

  • FDASpeculative

    Savara Inc.'s stock price could be affected by the uncertainty surrounding the molgramostim review.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped